- Home
- EYPT vs AQST Comparison
EYPT vs AQST Comparison
Compare EYPT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYPT
- AQST
- Stock Information
- Founded
- EYPT 1987
- AQST 2004
- Country
- EYPT United States
- AQST United States
- Employees
- EYPT N/A
- AQST N/A
- Industry
- EYPT Biotechnology: Laboratory Analytical Instruments
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- EYPT Industrials
- AQST Health Care
- Exchange
- EYPT Nasdaq
- AQST Nasdaq
- Market Cap
- EYPT 967.4M
- AQST 809.3M
- IPO Year
- EYPT 2005
- AQST 2018
- Fundamental
- Price
- EYPT $11.76
- AQST $6.64
- Analyst Decision
- EYPT Strong Buy
- AQST Strong Buy
- Analyst Count
- EYPT 5
- AQST 6
- Target Price
- EYPT $27.40
- AQST $10.33
- AVG Volume (30 Days)
- EYPT 1.4M
- AQST 3.1M
- Earning Date
- EYPT 11-05-2025
- AQST 11-05-2025
- Dividend Yield
- EYPT N/A
- AQST N/A
- EPS Growth
- EYPT N/A
- AQST N/A
- EPS
- EYPT N/A
- AQST N/A
- Revenue
- EYPT $51,898,000.00
- AQST $44,132,000.00
- Revenue This Year
- EYPT N/A
- AQST N/A
- Revenue Next Year
- EYPT N/A
- AQST $51.39
- P/E Ratio
- EYPT N/A
- AQST N/A
- Revenue Growth
- EYPT 2.99
- AQST N/A
- 52 Week Low
- EYPT $3.91
- AQST $2.12
- 52 Week High
- EYPT $14.91
- AQST $7.55
- Technical
- Relative Strength Index (RSI)
- EYPT 42.93
- AQST 54.50
- Support Level
- EYPT $11.15
- AQST $6.39
- Resistance Level
- EYPT $12.47
- AQST $7.18
- Average True Range (ATR)
- EYPT 0.68
- AQST 0.38
- MACD
- EYPT -0.08
- AQST -0.11
- Stochastic Oscillator
- EYPT 23.37
- AQST 21.55
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.